ClinicalTrials.gg
CompletedNCT01392443Updated Sep 3, 2019Results posted

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

A Phase 2 interventional study of Ruxolitinib in Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF and Post-Essential Thrombocythemia (ET) MF, sponsored by Novartis Pharmaceuticals. Completed at 26 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Oct 2010, registered Jul 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
9th of 50
120 · median 45
Started
2010
with 1 other
Phase 2
19 of 50
3 open now
Registered
9th of 50
by date
Lead sponsor
11 of 50
Novartis Pharmaceuticals

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 9th largest by enrollment, is one of 2 that started in 2010, is one of 19 in phase 2, and was the 9th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the effects of INC424 on patient reported outcomes and the duration of response as assessed by reduction in spleen volume was also assessed.

03

Conditions studied

  • Primary Myelofibrosis (MF)
  • Post-Polycythemia Vera (PV) MF
  • Post-Essential Thrombocythemia (ET) MF

Browse trials for

Keywords

  • Primary Myelofibrosis (MF)
  • Post-Polycythemia Vera (PV) MF
  • Post-Essential Thrombocythemia (ET) MF
  • post-PV MF
  • post-ET MF
  • INC424
  • Ruxolitinib
  • Myelofibrosis
  • MF
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years or older
  2. Diagnosis of primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF
  3. Enlarged spleen, measuring 5 cm or greater from the costal margin
  4. Must have two or more of the following risk factors:

    1. Over 65 years old
    2. Have the following symptoms often associated with MF: loss of weight, fever, night sweats
    3. Have a low red blood cell count (anemia - \< 10 g/dL)
    4. Have a high white blood cell count (history of white blood cell count > 25,000/uL)
    5. Have high circulating blasts (> or = 1%) as measured by blood tests
  5. Should have circulating blasts \<10% (as measured by blood tests)
  6. Should be capable of self-care
  7. Should have adequate bone marrow reserve
  8. Should not have the option of stem cell transplantation
  9. Should discontinue any prior or ongoing treatment for myelofibrosis prior to entering the study
  10. Had no prior treatment with another JAK inhibitor

Exclusion criteria

Exclusion Criteria:

  1. Does not have adequate liver or kidney function (as measured by blood tests)
  2. Has an active infection (bacterial, viral, etc.)
  3. Has active hepatitis A, B, or C or positive for
  4. Has another cancer that needs active intervention
  5. Had a history of bleeding disorder
  6. Had a history of very low counts (as measured by blood tests) not related to treatment of MF
  7. Had radiation of the spleen within 1 year of joining the study
  8. Does not have adequate heart function
  9. Sufficient time has elapsed between stopping previous treatment for MF and joining the study
  10. Females who are pregnant or breast-feeding
  11. Not able to sign
  12. Has any other active medical conditions that the doctor deems may compromise your safety or ability to join in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count \>200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.

    Drug: Ruxolitinib

Interventions

  • INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).

    Also known as: INC424

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24

    The primary measure of spleen size was by MRI. MRIs were performed with a body coil because the objective was to measure organ volume only, not to assess for lesions. MRIs were performed by local radiologists who were instructed not to provide a quantitative measure of spleen volume, but could provide a qualitative assessment such as enlarged, smaller, larger, etc. The scans from an individual patient were to be read by a central reader upon transfer from the site radiologist.

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Each Scheduled Time Point - Best Response

    The best response rate was defined as the proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline at any post-baseline assessment. The best response rate was estimated with an associated 95% confidence interval.

    Time frame: Weeks 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, at any time point

  2. Kaplan Meier Estimates of Duration of Response of at Least ≥ 35% Reduction From Baseline in Spleen Volume Per Kaplan Meier Estimates

    For patients who had at least one ≥ 35% reduction in spleen volume from baseline at postbaseline, the duration of response was calculated. The start date of the duration was defined as the first spleen volume measurement that was ≥ 35% reduction from baseline, and the end date of the response duration was defined as the earliest of the following: death, A ≥ 25% increase in spleen volume by MRI (or CT in applicable patients) compared to baseline, Splenic irradiation, Leukemic transformation as defined by a bone marrow or a peripheral blood blast count of ≥ 20%, Splenectomy. Duration of response is calculated only for participants who achieved at least one measured \>= 35% reduction in spleen volume at any time.

    Time frame: Weeks 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240

  3. Change in EORTC QLQ-C30 Scores From Baseline in at Week 24

    Patient reported outcomes regarding the impact of MF on patients were assessed using the EORTC QLQ-C30. Data from the EORTC QLQ-C30 questionnaire was analyzed using the standardized scores. There were 2 categories to this scale: Functional/QOL scale and Symptom and Other items scale. For each sub-scale, the raw scores were standardized in order to obtain scores ranging from 0 to 100. For Functional/QOL subscales: a higher score represents a higher/better level of functioning. For Symptoms and Other items subscales: a higher score represents worse level of symptoms. The absolute change from baseline was calculated for each scale and summarized descriptively by scheduled visit.

    Time frame: Baseline, Week 24

  4. Change in Total Symptom Score From Baseline at Week 24 as Measured by Seven-day Modified MFSAF v2.0

    The Seven-day modified MFSAF v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. Symptoms of myelofibrosis (MF) were assessed using this instrument \& included filling up quickly/early satiety, abdominal discomfort, pain under the ribs, night sweats, itching, bone/muscle pain \& inactivity. The first 6 items assessed MF symptom severity at its worst as recalled \& the seventh captured MF-related inactivity in the 7 days prior to the clinic visit assessment. All 7 items asked subjects to record their answers on an 11-point numeric rating scale (NRS) (0=Absent, 10=Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score, defined as the sum of the 6 individual symptom scores other than the inactivity score (each with 0-10 point scale) collected on the same week. The total symptom scale ranges from 0 -60 where higher score indicates a worse level of the condition.

    Time frame: Baseline, Week 24

07

Results

Posted Sep 3, 2019

Participant flow

A total of 110 patients were planned, 120 patients were enrolled and analyzed.

Participant flow — Overall Study
MilestoneRuxolitinib
Started120
Completed52
Not completed68
Withdrew: Disease progression30
Withdrew: Adverse event24
Withdrew: Death7
Withdrew: Withdrawal by subject5
Withdrew: Lost to follow-up1
Withdrew: Protocol violation1

Outcome measures

PrimaryPercentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24

The primary measure of spleen size was by MRI. MRIs were performed with a body coil because the objective was to measure organ volume only, not to assess for lesions. MRIs were performed by local radiologists who were instructed not to provide a quantitative measure of spleen volume, but could provide a qualitative assessment such as enlarged, smaller, larger, etc. The scans from an individual patient were to be read by a central reader upon transfer from the site radiologist.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24
ParticipantsRuxolitinib
Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 2438
Statistical analysis
  • Ruxolitinib · single-sample biniminal test · p = 0.0007
SecondaryPercentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Each Scheduled Time Point - Best Response

The best response rate was defined as the proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline at any post-baseline assessment. The best response rate was estimated with an associated 95% confidence interval.

Time frame:
Weeks 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, at any time point
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Each Scheduled Time Point - Best Response
Percentage of participantsRuxolitinib
Week 2435.8 (27.3 to 44.4)
Week 3640.0 (31.2 to 48.8)
Week 4844.2 (35.3 to 53.1)
Week 7244.2 (35.3 to 53.1)
Week 9645.8 (36.9 to 54.7)
Week 12045.8 (36.9 to 54.7)
Week 14446.7 (37.7 to 55.6)
Week 16847.5 (38.6 to 56.4)
Week 19247.5 (38.6 to 56.4)
Week 21647.5 (38.6 to 56.4)
Week 24047.5 (38.6 to 56.4)
at any time point47.5 (38.6 to 56.4)
SecondaryKaplan Meier Estimates of Duration of Response of at Least ≥ 35% Reduction From Baseline in Spleen Volume Per Kaplan Meier Estimates

For patients who had at least one ≥ 35% reduction in spleen volume from baseline at postbaseline, the duration of response was calculated. The start date of the duration was defined as the first spleen volume measurement that was ≥ 35% reduction from baseline, and the end date of the response duration was defined as the earliest of the following: death, A ≥ 25% increase in spleen volume by MRI (or CT in applicable patients) compared to baseline, Splenic irradiation, Leukemic transformation as defined by a bone marrow or a peripheral blood blast count of ≥ 20%, Splenectomy. Duration of response is calculated only for participants who achieved at least one measured \>= 35% reduction in spleen volume at any time.

Time frame:
Weeks 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240
Reported as:
Mean · weeks
Kaplan Meier Estimates of Duration of Response of at Least ≥ 35% Reduction From Baseline in Spleen Volume Per Kaplan Meier Estimates
weeksRuxolitinib
12 weeks1.00 (1.00 to 1.00)
24 weeks0.96 (0.86 to 0.99)
36 weeks0.96 (0.86 to 0.99)
48 weeks0.93 (0.82 to 0.97)
60 weeks0.93 (0.82 to 0.97)
72 weeks0.91 (0.79 to 0.96)
84 weeks0.89 (0.77 to 0.95)
96 weeks0.89 (0.77 to 0.95)
120 weeks0.89 (0.77 to 0.95)
144 weeks0.85 (0.71 to 0.93)
168 weeks0.79 (0.62 to 0.89)
192 weeks0.75 (0.57 to 0.86)
216 weeks0.75 (0.57 to 0.86)
240 weeksNA (NA to NA)
SecondaryChange in EORTC QLQ-C30 Scores From Baseline in at Week 24

Patient reported outcomes regarding the impact of MF on patients were assessed using the EORTC QLQ-C30. Data from the EORTC QLQ-C30 questionnaire was analyzed using the standardized scores. There were 2 categories to this scale: Functional/QOL scale and Symptom and Other items scale. For each sub-scale, the raw scores were standardized in order to obtain scores ranging from 0 to 100. For Functional/QOL subscales: a higher score represents a higher/better level of functioning. For Symptoms and Other items subscales: a higher score represents worse level of symptoms. The absolute change from baseline was calculated for each scale and summarized descriptively by scheduled visit.

Time frame:
Baseline, Week 24
Reported as:
Mean · scores on a scale
Change in EORTC QLQ-C30 Scores From Baseline in at Week 24
scores on a scaleRuxolitinib
Func./QOL scales: Global Health Status/QOL5.2 ± 22.04
Func./QOL scales: Physical Functioning0.6 ± 14.70
Func./QOL scales:Role Functioning-0.2 ± 21.54
Func./QOL scales: Emotional Functioning1.9 ± 14.14
Func./QOL scales: Cognitive Functioning-4.0 ± 18.43
Func./QOL scales: Social Functioning0.2 ± 21.41
Symptom and Other items: Fatigue-1.3 ± 20.32
Symptom & Other items: Nausea and Vomiting0.0 ± 9.43
Symptom and Other items: Pain-1.8 ± 18.99
Symptom and Other items: Dyspnea2.3 ± 25.93
Symptom and Other items: Insomnia-2.0 ± 30.12
Symptom and Other items: Appetite Loss-6.3 ± 25.26
Symptom and Other items: Constipation4.6 ± 20.02
Symptom and Other items: Diarrhea1.7 ± 23.75
Symptom & Other items: Fin. difficulties-2.0 ± 23.49
SecondaryChange in Total Symptom Score From Baseline at Week 24 as Measured by Seven-day Modified MFSAF v2.0

The Seven-day modified MFSAF v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. Symptoms of myelofibrosis (MF) were assessed using this instrument \& included filling up quickly/early satiety, abdominal discomfort, pain under the ribs, night sweats, itching, bone/muscle pain \& inactivity. The first 6 items assessed MF symptom severity at its worst as recalled \& the seventh captured MF-related inactivity in the 7 days prior to the clinic visit assessment. All 7 items asked subjects to record their answers on an 11-point numeric rating scale (NRS) (0=Absent, 10=Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score, defined as the sum of the 6 individual symptom scores other than the inactivity score (each with 0-10 point scale) collected on the same week. The total symptom scale ranges from 0 -60 where higher score indicates a worse level of the condition.

Time frame:
Baseline, Week 24
Reported as:
Median · scores on a scale
Change in Total Symptom Score From Baseline at Week 24 as Measured by Seven-day Modified MFSAF v2.0
scores on a scaleRuxolitinib
Change in Total Symptom Score From Baseline at Week 24 as Measured by Seven-day Modified MFSAF v2.0-5.0 (-27 to 21)

Adverse events

Collected over Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse Events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to 240 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib13/120 (10.8%)60/120 (50%)117/120 (97.5%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventRuxolitinib
PneumoniaInfections and infestations9/120
PyrexiaGeneral disorders8/120
Herpes zosterInfections and infestations6/120
Lung infectionInfections and infestations6/120
AnaemiaBlood and lymphatic system disorders5/120
Cardiac failureCardiac disorders3/120
BronchitisInfections and infestations3/120
GastroenteritisInfections and infestations2/120
SepsisInfections and infestations2/120
Blood bilirubin increasedInvestigations2/120
Most frequent other events
Showing 10 of 55
Most frequent other events
EventRuxolitinib
AnaemiaBlood and lymphatic system disorders87/120
Platelet count decreasedInvestigations44/120
DiarrhoeaGastrointestinal disorders42/120
Upper respiratory tract infectionInfections and infestations38/120
ThrombocytopeniaBlood and lymphatic system disorders34/120
CoughRespiratory, thoracic and mediastinal disorders31/120
PyrexiaGeneral disorders26/120
Alanine aminotransferase increasedInvestigations26/120
Abdominal distensionGastrointestinal disorders25/120
NasopharyngitisInfections and infestations24/120

Baseline characteristics

Full Analysis Set (FAS): comprised of all patients who received at least one dose of ruxolitinib.

Age, Continuous
Age, Continuous(Years)Ruxolitinib
Mean59.0 ± 12.25
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib
Female62
Male58
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib
Japanese30
Korean17
Chinese63
Taiwanese10
08

Study locations

26 sites
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 51000, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Suzhou, Jiangsu 215006, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300020, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Nagoya, Aichi 466 8560, Japan
  • Novartis Investigative Site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Maebashi city, Gunma 371 8511, Japan
  • Novartis Investigative Site
    Kanazawa-city, Ishikawa 920-8641, Japan
  • Novartis Investigative Site
    Tsu-city, Mie 514-8507, Japan
  • Novartis Investigative Site
    Suita city, Osaka 565 0871, Japan
  • Novartis Investigative Site
    Bunkyo ku, Tokyo 113 8655, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160 8582, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Novartis Investigative Site
    Seoul, Korea 06351, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Seocho Gu 06591, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Kaohsiung, 833, Taiwan
  • Novartis Investigative Site
    Taipei, 10048, Taiwan
  • Novartis Investigative Site
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Jin J, Du X, Zhou DB, Li JM, Li JY, Hou M, Liu T, Wu DP, Hu Y, Xiao ZJ. [Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202]. Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):858-863. doi: 10.3760/cma.j.issn.0253-2727.2016.10.007. Chinese. PubMed 27801315 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2010 to primary completion in Oct 2017, 84 months.

Results were first posted in Sep 2019, 1 year 10 months after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 84 months is above that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2011
First posted
Jul 12, 2011
StartActual
Oct 14, 2010
Primary completionActual
Oct 31, 2017
CompletionActual
Oct 31, 2017
Results first posted
Sep 3, 2019
Last update
Sep 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01392443
Responsible party
Sponsor
First posted
Jul 12, 2011
Start date
Oct 14, 2010
Primary completion
Oct 31, 2017
Completion
Oct 31, 2017
Results posted
Sep 3, 2019
Last update
Sep 3, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion